LONDON, Nov. 21, 2017 (GLOBE NEWSWIRE) -- The global high throughput screening market will grow at a CAGR of 8.0% from 2017 to 2022 to reach USD 21,911.2 million by 2022, according to Meticulous Research™. This market is primarily driven by the increasing adoption of innovative approaches in pharmaceutical and biotechnology companies, rising investment by private equity firms and venture capitalists, increasing government funding for various R&D activities, and various technological advancements in this field. However, high cost for HTS, intricacy in the field of assay development, and government regulations for drug development obstructs the growth of this market to some extent.
In products, the consumables & reagents segment dominated the overall market in 2016, owing to the availability of a wide variety of reagents, rising demand for consumables & reagents with increasing adoption of HTS in drug discovery, and continuous launch of innovative technology-based products in the global market.
Request Sample Report: http://www.meticulousresearch.com/request-sample-report/?cp_id=3206
In technology, cell-based assay segment commanded the largest share in 2016, owing to the large adoption of cell-based platforms to gain accurate and more relevant in vivo biological information in high-throughput drug screenings for target validation and ADMET in drug discovery. In case of end user, the pharmaceuticals & biotechnology industry dominated the high throughput screening market in 2016, owing to higher adoption of high throughput screening assay for drug discovery and development and regenerative medicine in this industry.
Geographically, North America dominated the global high throughput screening market in 2016, followed by Europe and Asia-Pacific region. However, Asia-Pacific region shall witness the fastest growth during the forecast period, primarily due to rising R&D expenditure, increasing pharmaceutical research outsourcing in the region owing to lower cost advantages, increasing government funding, and improving healthcare infrastructure.
The key players in this market are MERCK KGaA, Charles River Laboratories International, Inc., AXXAM S.p.A., Thermo Fisher Scientific Inc., Danaher Corporation, PerkinElmer Inc., Agilent Technologies Inc., Bio-Rad Laboratories, Inc., Tecan Trading AG, Aurora Biomed, Inc., and Hamilton Company.
Full News: http://www.meticulousresearch.com/global-high-throughput-screening-market-2022/
Scope:
High Throughput Screening Market, by Technology:
- Cell-based assay
- Ultra High Throughput Screening
- Label-Free Technology
- Lab on A Chip
High Throughput Screening Market, by Products & Services:
- Consumables & Reagents
- Instruments
- Software & Services
High Throughput Screening Market, by Application:
- Target Identification
- Toxicology Assessment
- Primary Screening
- Stem Cell Research
High Throughput Screening Market, by End User:
- Pharmaceuticals and Biotechnology Industry
- Academics and Research Institute
- Contract Research Organization
- Other End User
Browse in-depth Report at http://www.meticulousresearch.com/product/high-throughput-screening-market-forecast/
Contact Info:
Viren Shrivastava
AVP- Global Sales and Marketing
Meticulous Research™
Email: viren@meticulousresearch.com
Direct Lines: +1-646-781-8004 (North America)
+44-203-868-8738 (Europe)
+91 744-7780008 (Asia-Pacific)